Norihiro Watanabe

List of Publications by Year
in descending order

19	1,267	1040056 9	996975 15
papers	citations	h-index	g-index

19	19	19	1569
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Generation of CAR T-cells using Î³-retroviral vector. Methods in Cell Biology, 2022, 167, 171-183.	1.1	4
2	Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy. Cytotherapy, 2022, 24, 282-290.	0.7	4
3	Impact of Manufacturing Procedures on CAR T Cell Functionality. Frontiers in Immunology, 2022, 13, 876339.	4.8	54
4	Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Molecular Therapy, 2021, 29, 505-520.	8.2	48
5	Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nature Biotechnology, 2021, 39, 56-63.	17.5	71
6	Off-the-Shelf Chimeric Antigen Receptor T Cells. Cancer Journal (Sudbury, Mass), 2021, 27, 176-181.	2.0	4
7	Overcoming the breast tumor microenvironment by targeting MDSCs through CAR-T cell therapy.. Journal of Clinical Oncology, 2021, 39, 1032-1032.	1.6	2
8	Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. , 2021, 9, e003237.		29
9	Evaluation of cyclin A1â€“specific T cells as a potential treatment for acute myeloid leukemia. Blood Advances, 2020, 4, 387-397.	5.2	4
10	Modulating TNFÎ± activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. , 2020, 8, e001229.		29
11	Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia. Blood, 2020, 136, 22-23.	1.4	2
12	Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. , 2019, 7, 330.		18
13	CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. , 2018, 6, 34.		85
14	Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discovery, 2018, 8, 972-987.	9.4	93
15	Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Molecular Therapy, 2017, 25, 249-258.	8.2	217
16	Armed Oncolytic Adenovirusâ€“Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Research, 2017, 77, 2040-2051.	0.9	170
17	Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Molecular Therapy, 2017, 25, 2440-2451.	8.2	151
18	Fine-tuning the CAR spacer improves T-cell potency. OncoImmunology, 2016, 5, e1253656.	4.6	137

#	Article	IF	Citations
19	Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor. Molecular Therapy, 2014, 22, 1211-1220.	8.2	145